Ghost Approval: Transplant Drug Access 03/28/26
Welcome to Cardiology Today â Recorded March 28, 2026. This episode summarizes 5 key cardiology studies on topics like microvascular resistance and immunosuppressive therapy. Key takeaway: Ghost Approval: Transplant Drug Access.
Article Links:
Article 1: Tricuspid regurgitation: standardized stepwise work-up from referral to expert heart valve centre. (European heart journal)
Article 2: Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction. (European heart journal)
Article 3: Coronary autoregulation: the complex interplay between epicardial and microvascular resistance. (European heart journal)
Article 4: Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial. (JACC. Heart failure)
Article 5: When Coverage Is Not Access: A Heart Transplant Recipient’s Perspective on Everolimus, FDA Labeling, and the Problem of “Ghost Approval”. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/ghost-approval-transplant-drug-access-03-28-26/
đ Featured Articles
Article 1: Tricuspid regurgitation: standardized stepwise work-up from referral to expert heart valve centre.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41895721
Summary: A standardized stepwise work-up for Tricuspid Regurgitation was described, guiding patients from referral to an expert heart valve center. Optimal therapy selection for Tricuspid Regurgitation requires an integrated and systematic approach. This approach considers the condition’s etiology, disease stage, comorbidities, operative risk, and anatomical feasibility. Recent advances in surgical and transcatheter interventions have renewed focus on Tricuspid Regurgitation, a common condition historically associated with poor outcomes.
Article 2: Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41895321
Summary: This study evaluated the association between Atrial Fibrillation density and ischaemic stroke, investigating whether this temporal episode distribution improves risk stratification compared to Atrial Fibrillation burden. The research utilized data from two U.S. cohorts of patients with cardiac implantable electronic devices that were remotely monitored by the Veterans Health Administration. Atrial Fibrillation density was considered as a potentially more clinically relevant and prognostically important biomarker than traditional classifications based on episode duration or cumulative burden.
Article 3: Coronary autoregulation: the complex interplay between epicardial and microvascular resistance.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41895317
Summary: Coronary autoregulation maintains stable blood flow in the coronary circulation despite fluctuations in myocardial perfusion pressure, provided metabolic demands remain constant. The dynamic modulation of microvascular resistance within the coronary microcirculation determines coronary blood flow and is central to this regulatory process. This intrinsic mechanism enables the coronary vasculature to adapt to variations in aortic pressure and epicardial resistance.
Article 4: Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41893376
Summary: A post hoc analysis from the P. U. S. H. hyphen A. H. F. trial evaluated the efficacy of natriuresis-guided diuretic therapy in patients with acute decompensated heart failure at risk of diuretic resistance. Diuretic resistance is common in acute decompensated heart failure and is associated with residual congestion and poor prognosis. The study identified diuretic resistance risk using the B. A. N. hyphen A. D. H. F. score, which incorporates blood urea nitrogen, creatinine, natriuretic peptide levels, atrial fibrillation, diastolic blood pressure, hypertension, and home diuretics.
Article 5: When Coverage Is Not Access: A Heart Transplant Recipient’s Perspective on Everolimus, FDA Labeling, and the Problem of “Ghost Approval”.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41895624
Summary: This perspective piece introduced the concept of “ghost approval,” where a technically approved medication remains financially or logistically inaccessible to the patient. It highlights that access to immunosuppressive therapy is essential for long-term survival in heart transplant recipients. A first-person experience with everolimus, an M. T. O. R. inhibitor, exemplified this issue, noting its lack of a U.S. Food and Drug Administration indication for heart transplantation contributed to access challenges.
đ Transcript
Today’s date is March 28, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Tricuspid regurgitation: standardized stepwise work-up from referral to expert heart valve centre. A standardized stepwise work-up for Tricuspid Regurgitation was described, guiding patients from referral to an expert heart valve center. Optimal therapy selection for Tricuspid Regurgitation requires an integrated and systematic approach. This approach considers the condition’s etiology, disease stage, comorbidities, operative risk, and anatomical feasibility. Recent advances in surgical and transcatheter interventions have renewed focus on Tricuspid Regurgitation, a common condition historically associated with poor outcomes.
Article number two. Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction. This study evaluated the association between Atrial Fibrillation density and ischaemic stroke, investigating whether this temporal episode distribution improves risk stratification compared to Atrial Fibrillation burden. The research utilized data from two U.S. cohorts of patients with cardiac implantable electronic devices that were remotely monitored by the Veterans Health Administration. Atrial Fibrillation density was considered as a potentially more clinically relevant and prognostically important biomarker than traditional classifications based on episode duration or cumulative burden.
Article number three. Coronary autoregulation: the complex interplay between epicardial and microvascular resistance. Coronary autoregulation maintains stable blood flow in the coronary circulation despite fluctuations in myocardial perfusion pressure, provided metabolic demands remain constant. The dynamic modulation of microvascular resistance within the coronary microcirculation determines coronary blood flow and is central to this regulatory process. This intrinsic mechanism enables the coronary vasculature to adapt to variations in aortic pressure and epicardial resistance.
Article number four. Diuretic Resistance Risk and the Efficacy of Natriuresis-Guided Diuretic Therapy in Acute Heart Failure: Post Hoc Analysis From the PUSH-AHF Trial. A post hoc analysis from the P. U. S. H. hyphen A. H. F. trial evaluated the efficacy of natriuresis-guided diuretic therapy in patients with acute decompensated heart failure at risk of diuretic resistance. Diuretic resistance is common in acute decompensated heart failure and is associated with residual congestion and poor prognosis. The study identified diuretic resistance risk using the B. A. N. hyphen A. D. H. F. score, which incorporates blood urea nitrogen, creatinine, natriuretic peptide levels, atrial fibrillation, diastolic blood pressure, hypertension, and home diuretics.
Article number five. When Coverage Is Not Access: A Heart Transplant Recipient’s Perspective on Everolimus, FDA Labeling, and the Problem of “Ghost Approval”. This perspective piece introduced the concept of “ghost approval,” where a technically approved medication remains financially or logistically inaccessible to the patient. It highlights that access to immunosuppressive therapy is essential for long-term survival in heart transplant recipients. A first-person experience with everolimus, an M. T. O. R. inhibitor, exemplified this issue, noting its lack of a U.S. Food and Drug Administration indication for heart transplantation contributed to access challenges.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
microvascular resistance, immunosuppressive therapy, heart valve disease, ischaemic stroke, Heart transplantation, P. U. S. H. hyphen A. H. F. trial, acute decompensated heart failure, ghost approval, risk stratification, Coronary autoregulation, Diuretic resistance, Atrial fibrillation, myocardial perfusion, natriuresis-guided therapy, prognosis, surgical intervention, cardiac implantable electronic device, coronary circulation, patient work-up, blood flow regulation, transcatheter intervention, everolimus, biomarker, Tricuspid regurgitation, U.S. Food and Drug Administration.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow